Condition
Metastatic Malignant Germ Cell Tumor
Total Trials
2
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Active Not Recruiting1
Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07218913Phase 1Recruiting
Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors
NCT02721732Phase 2Active Not Recruiting
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
Showing all 2 trials